-
1
-
-
84860144206
-
American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis
-
Jellinger P.S., Smith D.A., Mehta A.E., et al. American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract 2012, 18(Suppl 1):1-78.
-
(2012)
Endocr Pract
, vol.18
, Issue.SUPPL 1
, pp. 1-78
-
-
Jellinger, P.S.1
Smith, D.A.2
Mehta, A.E.3
-
2
-
-
81855224663
-
AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association
-
Smith S.C., Benjamin E.J., Bonow R.O., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. JAm Coll Cardiol 2011, 58(23):2432-2446.
-
(2011)
JAm Coll Cardiol
, vol.58
, Issue.23
, pp. 2432-2446
-
-
Smith, S.C.1
Benjamin, E.J.2
Bonow, R.O.3
-
3
-
-
77951944375
-
The myth of statin-induced hepatotoxicity
-
Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol 2010, 105:978-980. 10.1038/ajg.2010.102.
-
(2010)
Am J Gastroenterol
, vol.105
, pp. 978-980
-
-
Bader, T.1
-
4
-
-
0026557541
-
HMG-CoA reductase inhibitors
-
Hunninghake D.B. HMG-CoA reductase inhibitors. Curr Opin Lipidol 1992, 3:22-28.
-
(1992)
Curr Opin Lipidol
, vol.3
, pp. 22-28
-
-
Hunninghake, D.B.1
-
5
-
-
0037490080
-
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
-
Law M.R., Wald N.J., Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003, 326:1423.
-
(2003)
BMJ
, vol.326
, pp. 1423
-
-
Law, M.R.1
Wald, N.J.2
Rudnicka, A.R.3
-
6
-
-
77956025285
-
Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians
-
Rzouq F.S., Volk M.L., Hatoum H.H., et al. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci 2010, 340:89-93.
-
(2010)
Am J Med Sci
, vol.340
, pp. 89-93
-
-
Rzouq, F.S.1
Volk, M.L.2
Hatoum, H.H.3
-
7
-
-
2342565003
-
Statins and liver toxicity: a meta-analysis
-
De Denus S., Spinler S.A., Miller K., et al. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004, 24:584-591.
-
(2004)
Pharmacotherapy
, vol.24
, pp. 584-591
-
-
De Denus, S.1
Spinler, S.A.2
Miller, K.3
-
8
-
-
33645881669
-
Statin safety: a systematic review
-
Law M., Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 2006, 97(8A):52C-60C.
-
(2006)
Am J Cardiol
, vol.97
, Issue.8 A
-
-
Law, M.1
Rudnicka, A.R.2
-
9
-
-
0026088892
-
Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia
-
Bradford R.H., Shear C.L., Chremos A.N., et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 1991, 151(1):43-49.
-
(1991)
Arch Intern Med
, vol.151
, Issue.1
, pp. 43-49
-
-
Bradford, R.H.1
Shear, C.L.2
Chremos, A.N.3
-
10
-
-
0027987849
-
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
-
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344(8934):1383-1389.
-
(1994)
Lancet
, vol.344
, Issue.8934
, pp. 1383-1389
-
-
-
11
-
-
65749097599
-
Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people
-
MRC/BHF Heart Protection Study Collaborative Group
-
MRC/BHF Heart Protection Study Collaborative Group, Armitage J., Bowman L., Collins R., et al. Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people. BMC Clin Pharmacol 2009, 9:6.
-
(2009)
BMC Clin Pharmacol
, vol.9
, pp. 6
-
-
Armitage, J.1
Bowman, L.2
Collins, R.3
-
12
-
-
0028883828
-
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
-
West of Scotland Coronary Prevention Study Group (WOS) et al.
-
Shepherd J., Cobbe S.M., Ford I., for the West of Scotland Coronary Prevention Study Group (WOS), et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEngl J Med 1995, 333:1301-1307.
-
(1995)
NEngl J Med
, vol.333
, pp. 1301-1307
-
-
Shepherd, J.1
Cobbe, S.M.2
Ford, I.3
-
13
-
-
0032487931
-
The Long-term Intervention with Pravastatin in Ischemic Disease Group (LIPID). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
-
The Long-term Intervention with Pravastatin in Ischemic Disease Group (LIPID). Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. NEngl J Med 1998, 339:1349-1357.
-
(1998)
NEngl J Med
, vol.339
, pp. 1349-1357
-
-
-
14
-
-
0342981862
-
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
-
Cholesterol and Recurrent Events Trial Investigators (CARE) et al.
-
Sacks F.M., Pfeffer M.A., Moye L.A., for the Cholesterol and Recurrent Events Trial Investigators (CARE), et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. NEngl J Med 1996, 335:1001-1009.
-
(1996)
NEngl J Med
, vol.335
, pp. 1001-1009
-
-
Sacks, F.M.1
Pfeffer, M.A.2
Moye, L.A.3
-
15
-
-
53549104055
-
The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care
-
Garcia-Rodriguez L.A., Masso-Gonzalez E.L., Wallander M.A., et al. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care. Pharmacoepidemiol Drug Saf 2008, 17:943-952.
-
(2008)
Pharmacoepidemiol Drug Saf
, vol.17
, pp. 943-952
-
-
Garcia-Rodriguez, L.A.1
Masso-Gonzalez, E.L.2
Wallander, M.A.3
-
16
-
-
36749013849
-
Atorvastatin: a safety and tolerability profile
-
Arca M. Atorvastatin: a safety and tolerability profile. Drugs 2007, 67(Suppl 1):63-69.
-
(2007)
Drugs
, vol.67
, Issue.SUPPL 1
, pp. 63-69
-
-
Arca, M.1
-
17
-
-
34547559566
-
Impact of statin dosing intensity on transaminase and creatine kinase
-
Dale K.M., White C.M., Henyan N.N., et al. Impact of statin dosing intensity on transaminase and creatine kinase. Am J Med 2007, 120(8):706-712.
-
(2007)
Am J Med
, vol.120
, Issue.8
, pp. 706-712
-
-
Dale, K.M.1
White, C.M.2
Henyan, N.N.3
-
18
-
-
29244483080
-
Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients
-
Newman C., Tsai J., Szarek M., et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006, 97(1):61-67.
-
(2006)
Am J Cardiol
, vol.97
, Issue.1
, pp. 61-67
-
-
Newman, C.1
Tsai, J.2
Szarek, M.3
-
19
-
-
34447627450
-
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials
-
Alsheikh-Ali A.A., Maddukuri P.V., Han H., et al. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. JAm Coll Cardiol 2007, 50:409-418.
-
(2007)
JAm Coll Cardiol
, vol.50
, pp. 409-418
-
-
Alsheikh-Ali, A.A.1
Maddukuri, P.V.2
Han, H.3
-
20
-
-
33645870418
-
Statin safety: lessons from new drug applications for marketed statins
-
Jacobson T.A. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006, 97(8A):44C-51C.
-
(2006)
Am J Cardiol
, vol.97
, Issue.8 A
-
-
Jacobson, T.A.1
-
21
-
-
0034048191
-
Defining patient risks from expanded preventive therapies
-
Tolman K.G. Defining patient risks from expanded preventive therapies. Am J Cardiol 2000, 85:15E-19E.
-
(2000)
Am J Cardiol
, vol.85
-
-
Tolman, K.G.1
-
22
-
-
84855970707
-
Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing
-
Björnsson E., Jacobsen E.I., Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. JHepatol 2012, 56(2):374-380. 10.1016/j.jhep.2011.07.023.
-
(2012)
JHepatol
, vol.56
, Issue.2
, pp. 374-380
-
-
Björnsson, E.1
Jacobsen, E.I.2
Kalaitzakis, E.3
-
23
-
-
2942705774
-
Safety of statins: focus on clinical pharmacokinetics and drug interactions
-
Bellosta S., Paoletti R., Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004, 109(23 Suppl 1):III50-III57.
-
(2004)
Circulation
, vol.109
, Issue.23 SUPPL 1
, pp. 350-357
-
-
Bellosta, S.1
Paoletti, R.2
Corsini, A.3
-
24
-
-
7044237064
-
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors
-
Jacobson T.A. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004, 94(9):1140-1146.
-
(2004)
Am J Cardiol
, vol.94
, Issue.9
, pp. 1140-1146
-
-
Jacobson, T.A.1
-
25
-
-
10744229858
-
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
-
Holdaas H., Fellström B., Jardine A.G., et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003, 361(9374):2024-2031.
-
(2003)
Lancet
, vol.361
, Issue.9374
, pp. 2024-2031
-
-
Holdaas, H.1
Fellström, B.2
Jardine, A.G.3
-
26
-
-
77949312879
-
Statins improve ALT values in chronic hepatitis C patients with abnormal values
-
Madhoun M.F., Bader T. Statins improve ALT values in chronic hepatitis C patients with abnormal values. Dig Dis Sci 2010, 55:870-871.
-
(2010)
Dig Dis Sci
, vol.55
, pp. 870-871
-
-
Madhoun, M.F.1
Bader, T.2
-
27
-
-
33745591910
-
Incidence of statin hepatotoxicity in patients with hepatitis C
-
[quiz: 806]
-
Khorashadi S., Hasson N.K., Cheung R.C. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 2006, 4(7):902-907. [quiz: 806].
-
(2006)
Clin Gastroenterol Hepatol
, vol.4
, Issue.7
, pp. 902-907
-
-
Khorashadi, S.1
Hasson, N.K.2
Cheung, R.C.3
-
28
-
-
44949165396
-
Fluvastatin inhibits hepatitis C replication in humans
-
Bader T., Fazili J., Madhoun M., et al. Fluvastatin inhibits hepatitis C replication in humans. Am J Gastroenterol 2008, 103:1383-1389.
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 1383-1389
-
-
Bader, T.1
Fazili, J.2
Madhoun, M.3
-
29
-
-
0036791192
-
Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day versus Daily Dosing of Atorvastatin Study (ADDAS)
-
Matalka M.S., Ravnan M.C., Deedwania P.C. Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J 2002, 144:674-677.
-
(2002)
Am Heart J
, vol.144
, pp. 674-677
-
-
Matalka, M.S.1
Ravnan, M.C.2
Deedwania, P.C.3
-
30
-
-
78649890465
-
Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post hoc analysis
-
Athyros V.G., Tziomalos K., Gossios T.D., et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post hoc analysis. Lancet 2010, 376:1916-1922.
-
(2010)
Lancet
, vol.376
, pp. 1916-1922
-
-
Athyros, V.G.1
Tziomalos, K.2
Gossios, T.D.3
-
31
-
-
78649824344
-
Liver tests are irrelevant when prescribing statins
-
Bader T. Liver tests are irrelevant when prescribing statins. Lancet 2010, 376:1882-1883.
-
(2010)
Lancet
, vol.376
, pp. 1882-1883
-
-
Bader, T.1
-
32
-
-
36348987648
-
Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial
-
Lewis J.H., Mortensen M.E., Zweig S., et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology 2007, 46(5):1453-1463.
-
(2007)
Hepatology
, vol.46
, Issue.5
, pp. 1453-1463
-
-
Lewis, J.H.1
Mortensen, M.E.2
Zweig, S.3
-
33
-
-
33645888317
-
An assessment of statin safety by hepatologists
-
Cohen D., Anania F., Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006, 97:C77-C81.
-
(2006)
Am J Cardiol
, vol.97
-
-
Cohen, D.1
Anania, F.2
Chalasani, N.3
-
34
-
-
0037300357
-
Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment
-
Simonson S.G., Martin P.D., Mitchell P., et al. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol 2003, 58(10):669-675.
-
(2003)
Eur J Clin Pharmacol
, vol.58
, Issue.10
, pp. 669-675
-
-
Simonson, S.G.1
Martin, P.D.2
Mitchell, P.3
-
35
-
-
41549137855
-
Safety of statin therapy in patients with preexisting liver disease
-
Onofrei M.D., Butler K.L., Fuke D.C., et al. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy 2008, 28(4):522-529.
-
(2008)
Pharmacotherapy
, vol.28
, Issue.4
, pp. 522-529
-
-
Onofrei, M.D.1
Butler, K.L.2
Fuke, D.C.3
-
36
-
-
65349094504
-
Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial
-
Abraldes J.G., Albillos A., Bañares R., et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 2009, 136:1651-1658.
-
(2009)
Gastroenterology
, vol.136
, pp. 1651-1658
-
-
Abraldes, J.G.1
Albillos, A.2
Bañares, R.3
-
37
-
-
20444371945
-
The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)
-
Garcia-Calvo M., Lisnock J., Bull H.G., et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl Acad Sci USA 2005, 102:8132-8137.
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, pp. 8132-8137
-
-
Garcia-Calvo, M.1
Lisnock, J.2
Bull, H.G.3
-
38
-
-
0037111890
-
Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia
-
Gagné C., Bays H.E., Weiss S.R., et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002, 90:1084-1091.
-
(2002)
Am J Cardiol
, vol.90
, pp. 1084-1091
-
-
Gagné, C.1
Bays, H.E.2
Weiss, S.R.3
-
39
-
-
0038054346
-
Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies
-
Knopp R.H., Dujovne C.A., Le Beaut A., et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003, 57:363-368.
-
(2003)
Int J Clin Pract
, vol.57
, pp. 363-368
-
-
Knopp, R.H.1
Dujovne, C.A.2
Le Beaut, A.3
-
40
-
-
49349107489
-
Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years
-
Dujovne C.A., Suresh R., McCrary Sisk C., et al. Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years. Int J Clin Pract 2008, 62:1332-1336.
-
(2008)
Int J Clin Pract
, vol.62
, pp. 1332-1336
-
-
Dujovne, C.A.1
Suresh, R.2
McCrary Sisk, C.3
-
41
-
-
58149137193
-
Xavier Xiol Serious drug-induced liver disease secondary to ezetimibe
-
Castellote J., Ariza J., Rota R., et al. Xavier Xiol Serious drug-induced liver disease secondary to ezetimibe. World J Gastroenterol 2008, 14(32):5098-5099.
-
(2008)
World J Gastroenterol
, vol.14
, Issue.32
, pp. 5098-5099
-
-
Castellote, J.1
Ariza, J.2
Rota, R.3
-
42
-
-
27844560120
-
Ezetimibe/simvastatin (Vytorin) for hypercholesterolemia
-
Goldman-Levine J.D., Bohlman L.G. Ezetimibe/simvastatin (Vytorin) for hypercholesterolemia. Am Fam Physician 2005, 72:2081-2082.
-
(2005)
Am Fam Physician
, vol.72
, pp. 2081-2082
-
-
Goldman-Levine, J.D.1
Bohlman, L.G.2
-
43
-
-
75649136240
-
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither
-
Conard S., Bays H., Leiter L.A., et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab 2010, 12:210-218.
-
(2010)
Diabetes Obes Metab
, vol.12
, pp. 210-218
-
-
Conard, S.1
Bays, H.2
Leiter, L.A.3
-
45
-
-
0021350001
-
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
-
The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984, 251(3):351-364.
-
(1984)
JAMA
, vol.251
, Issue.3
, pp. 351-364
-
-
-
46
-
-
0023879688
-
The Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia
-
The Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA 1988, 260:359-366.
-
(1988)
JAMA
, vol.260
, pp. 359-366
-
-
-
47
-
-
0035071170
-
Colestipol-induced hepatotoxicity
-
Sirmans S.M., Beck J.K., Banh H.L., et al. Colestipol-induced hepatotoxicity. Pharmacotherapy 2001, 21(4):513-516.
-
(2001)
Pharmacotherapy
, vol.21
, Issue.4
, pp. 513-516
-
-
Sirmans, S.M.1
Beck, J.K.2
Banh, H.L.3
-
48
-
-
73949102364
-
Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes
-
Goldfine A.B., Fonseca V.A., Jones M.R., et al. Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm Metab Res 2010, 42:23-30.
-
(2010)
Horm Metab Res
, vol.42
, pp. 23-30
-
-
Goldfine, A.B.1
Fonseca, V.A.2
Jones, M.R.3
-
49
-
-
79955109060
-
Important considerations for treatment with dietary supplement versus prescription niacin products
-
Backes J.M., Padley R.J., Moriarty P.M. Important considerations for treatment with dietary supplement versus prescription niacin products. Postgrad Med 2011, 123:70-83.
-
(2011)
Postgrad Med
, vol.123
, pp. 70-83
-
-
Backes, J.M.1
Padley, R.J.2
Moriarty, P.M.3
-
50
-
-
0028057319
-
Acomparison of the efficacy and toxic effects of sustained versus immediate release niacin in hypercholesterolemic patients
-
Mckenney J.M., Proctor J.D., Harris S., et al. Acomparison of the efficacy and toxic effects of sustained versus immediate release niacin in hypercholesterolemic patients. JAMA 1994, 271:672-677.
-
(1994)
JAMA
, vol.271
, pp. 672-677
-
-
Mckenney, J.M.1
Proctor, J.D.2
Harris, S.3
-
51
-
-
57149105884
-
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study
-
Mohiuddin S.M., Pepine C.J., Kelly M.T., et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. Am Heart J 2009, 157(1):195-203.
-
(2009)
Am Heart J
, vol.157
, Issue.1
, pp. 195-203
-
-
Mohiuddin, S.M.1
Pepine, C.J.2
Kelly, M.T.3
-
52
-
-
72249115539
-
Does simvastatin cause more myotoxicity compared with other statins?
-
Backes J.M., Howard P.A., Ruisinger J.F., et al. Does simvastatin cause more myotoxicity compared with other statins?. Ann Pharmacother 2009, 43:2012-2020.
-
(2009)
Ann Pharmacother
, vol.43
, pp. 2012-2020
-
-
Backes, J.M.1
Howard, P.A.2
Ruisinger, J.F.3
-
53
-
-
0032788490
-
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders
-
Murdock D.K., Murdock A.K., Murdock R.W., et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J 1999, 138:151-155.
-
(1999)
Am Heart J
, vol.138
, pp. 151-155
-
-
Murdock, D.K.1
Murdock, A.K.2
Murdock, R.W.3
-
54
-
-
0030882897
-
Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia
-
Athyros V.G., Papageorgiou A.A., Hatzikonstandinou H.A., et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997, 80:608-613.
-
(1997)
Am J Cardiol
, vol.80
, pp. 608-613
-
-
Athyros, V.G.1
Papageorgiou, A.A.2
Hatzikonstandinou, H.A.3
-
55
-
-
0033016149
-
The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment
-
Riegger G., Abletshauser C., Ludwig M., et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis 1999, 144(1):263-270.
-
(1999)
Atherosclerosis
, vol.144
, Issue.1
, pp. 263-270
-
-
Riegger, G.1
Abletshauser, C.2
Ludwig, M.3
|